# InfraReDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infraredx

- Industry: Medical Devices & Equipment
- Headquarters: Burlington, US
- Website: www.infraredx.com
- Total disclosed funding: $72M
- Latest round: Series E (Aug 22, 2013)
- Investors on record: 2

## About

InfraReDx Inc. specializes in advanced intravascular imaging technologies to improve the diagnosis and treatment of coronary artery disease, focusing on enhanced patient outcomes through innovative medical solutions.InfraReDx Inc. was founded in 1998 in Burlington, US, and operates in the field of intravascular imaging technology. The company has executed 13 deals, with its most recent funding occurring on October 1, 2015, when Nipro Medical Corporation invested USD 25.00 mn, bringing the total amount raised to USD 25.00 mn.Infraredx™, Inc. specializes in high-resolution intravascular imaging technologies designed to enhance the diagnosis and treatment of coronary artery disease. Their core product offerings include the Clarispro® HD-IVUS, which provides advanced vessel structure visualization; the Dualpro® IVUS+ NIRS, which is engineered to identify unstable lipid-core plaques that can contribute to serious cardiac events; and the Makoto® Imaging System, an innovative platform that combines high-resolution structural imaging with plaque compositional analysis for improved treatment insights. These products are primarily aimed at healthcare institutions, cardiovascular specialists, and interventional cardiologists focusing on delivering better patient outcomes in diagnosing and managing vascular diseases. Infraredx operates in various geographical markets, including North America, Europe, and Asia, positioning itself as a vital player in the coronary artery disease treatment landscape.Infraredx™ generates revenue through direct sales of its sophisticated imaging systems and related accessories to healthcare facilities and professionals. The company’s transaction structure typically involves B2B sales relationships, where products are sold to hospitals, clinics, and specialist practices focusing on cardiovascular care. The flagship products, such as the Clarispro® HD-IVUS and the Dualpro® IVUS+ NIRS, are sold under structured pricing agreements that reflect their advanced technological capabilities and the critical role they play in patient care. Sales transactions may include one-time purchases along with potential agreements for ongoing service and support, ensuring customers receive comprehensive solutions tailored to their operational needs.InfraReDx Inc. is focused on future growth through the development of new products and expansion into new markets. They aim to enhance their product lineup with upcoming innovations designed to improve patient care, although specific release dates for these products have not been disclosed. The company also plans to expand its operations into new geographical regions, targeting additional markets in North America, Europe, and Asia by 2016. The proceeds from the October 2015 investment of USD 25.00 mn by Nipro Corporation will support these initiatives, reinforcing InfraReDx's commitment to enhancing its technology and market presence.

## Funding rounds

- Series E, Aug 22, 2013, $25M — Sanderling Ventures
- Series D, Oct 7, 2010, $21M — Sanderling Ventures
- Series C, Jul 30, 2008, $7.3M — Sanderling Ventures
- Series A, Dec 27, 2006, $3.3M — Sanderling Ventures, ArchAngel BioVentures
- Series B, Jun 30, 2006, $8M — Sanderling Ventures
- Series A, Apr 27, 2005, $2.8M — Sanderling Ventures
- Series A, Jul 31, 2003, $4.4M — Sanderling Ventures

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A, Series B, Series C, Series D, Series E
- ArchAngel BioVentures — Series A